Efficacy, safety and tolerability of XBD173 in patients with generalized anxiety disorder
Phase of Trial: Phase II
Latest Information Update: 19 May 2010
At a glance
- Drugs XBD 173 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 May 2010 Last checked against ClinicalTrials.gov record.
- 28 Nov 2007 Status changed from in progress to completed
- 30 Jan 2006 New trial record.